	US 11,807,906 B2
	Peroxisome biomarkers in HIV disease progression and peroxisome activating drugs for HIV treatment
Tom C. Hobman, Edmonton (CA); Chris Power, Edmonton (CA); and Zaikun Xu, Edmonton (CA)
Appl. No. 16/606,665
Filed by THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, Edmonton (CA)
PCT Filed May 7, 2018, PCT No. PCT/CA2018/050541 § 371(c)(1), (2) Date Oct. 18, 2019, PCT Pub. No. WO2018/205016, PCT Pub. Date Nov. 15, 2018.
Claims priority of provisional application 62/503,182, filed on May 8, 2017.
Prior Publication US 2020/0340056 A1, Oct. 29, 2020
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); A61P 31/18 (2006.01); A61K 31/167 (2006.01)

CPC C12Q 1/6883 (2013.01) [A61K 31/167 (2013.01); A61P 31/18 (2018.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)]

4 Claims

1. A method of treating a HIV patient diagnosed as having an increased risk for developing human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND), the method comprising:

administering a peroxisome proliferator comprising 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide (CAS No. 50-65-7), or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, or fenofibrate or a derivative or salt thereof, to the patient in an amount effective to treat HIV,

wherein the HIV patient has been diagnosed as having an increased risk for developing HAND by:

(i) detecting an increased level of miR-500a-5p, miR-34c-3p, miR-93-3p, and/or miR-381-3p relative to a control; or

(ii) detecting a decreased level of a peroxin selected from the group consisting of PEX2, PEX19, PEX7, PEX11B, and PEX13, relative to a control.